Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced a collaboration with Predicta Biosciences to commercially expand access to GenoPredicta, a co-branded whole-genome sequencing assay for hematologic malignancies and measurable residual disease monitoring. Here’s what investors need to know.
- Tempus AI stock is surging to new heights today. Why is TEM stock up today?
Ultrasensitive Assay Expands Testing Reach
The company said the assay combines flow cytometry with whole-genome sequencing to deliver deep genomic insights from peripheral blood or bone marrow, with sensitivity down to as few as 50 tumor cells, or roughly one in a million cells.
Tempus said that level of sensitivity could broaden testing eligibility in low-tumor-burden cases and help identify mutations, risk markers and therapy resistance mechanisms.
The test is already available to Tempus’ Life Sciences partners for exploratory research and clinical development work. Tempus added that the assay has been clinically validated in multiple myeloma and other plasma cell dyscrasias, while remaining available for research use only in other indications.
Single-Workflow Approach May Reduce Biopsy Burden
Management framed the collaboration as a way to consolidate traditional siloed testing into a single workflow, while also potentially reducing the need for invasive bone marrow biopsies because the assay showed 100% concordance between peripheral blood and bone marrow.
RSI Trend Shows Momentum Building In Tempus Stock
Tempus AI’s RSI has spent most of the past six months in the neutral range (30–70), with multiple dips into oversold territory near 30 and no sustained overbought conditions.
Recently, RSI has spiked sharply higher toward the upper end of the range, signaling strengthening momentum but still below overbought levels.
Tempus Faces Its Next Key Catalyst With May Earnings
Looking further out, the next major catalyst for the stock arrives with the May 5 (estimated) earnings report.
- EPS Estimate: Loss of 29 cents (Down from a loss of 24 cents YoY)
- Revenue Estimate: $345.46 million (Up from $255.74 million YoY)
Analyst Consensus Still Favors Upside In Tempus Stock
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $73.09. Recent analyst moves include:
- Jefferies: Initiated with Underperform (Target $35.00) (April 13)
- Guggenheim: Buy (Lowers Target to $60.00) (March 30)
- Needham: Buy (Maintains Target to $75.00) (March 11)
TEM Shares Surge Wednesday Afternoon
TEM Price Action: Tempus AI shares were up 10.76% at $54.86 at the time of publication on Wednesday, according to Benzinga Pro data.
Image: Shutterstock
Recent Comments